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Summary
Background:  Drug-resistant  epilepsy  (DRE)  is  usually  related  to  focal  epilepsy  (FE)  and  is  present
in up  to  30%  of  patients.  Several  studies  have  found  high  rates  of  depressive  symptoms  and  poor
health related  quality  of  life  (HRQOL)  in  DRE  patients  but  little  information  is  available  on  these
aspects for  Spain.
Objective:  To  determine  the  prevalence  of  depressive  symptoms  in  a  cohort  of  Spanish  patients
with DRE  and  evaluate  their  HRQOL  in  comparison  with  patients  with  controlled  FE  (CFE).
Methods:  This  observational  cross-sectional  study  analyzed  FE  patients,  with  and  without  DRE,
recruited from  different  Spanish  neurology  outpatient  clinics.  Presence  of  depressive  symp-
toms was  assessed  using  the  Montgomery—Asberg  Depression  Rating  Scale  (MADRS)  and  the
Beck Depression  Inventory-II  (BDI-II).  HRQOL  was  evaluated  using  the  Quality  of  Life  in  Epilepsy
Inventory (QOLIE-31).
Results:  515  patients  (DRE  =  248)  were  included.  Mean  (SD)  age  was  44.3  (15.4)  years  and
50.5% were  male.  Overall,  15.9%  had  a  previous  diagnosis  of  depressive  symptoms  (DRE  =  22.6%;
CFE =  9.7%,  p  <  0.001).  Depressive  symptoms  was  observed  in  62.1%  [95%  CI  56.1—68.1]  and
64.8% [58.8—70.7]  of  DRE  patients  using  MADRS  and  BDI-II,  respectively,  compared  to  32.6%
[27.0—38.2] and  37.2%  [31.4—43.0]  in  the  CFE  group  (p  <  0.001).  Depressive  symptoms  was  asso-
ciated with  poorer  HRQOL.  Multivariate  modeling  showed  that  presence  of  depressive  symptoms
on the  MADRS  or  BDI-II  had  the  greatest  impact  on  mean  QOLIE-31  scores.
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Conclusions:  Compared  to  other  
and 30%  in  CFE  patients).  MADRS
depressive  symptoms  were  under
of depressive  symptoms  and  not  
scores.
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ocal  epilepsy  has  been  estimated  to  account  for  20—66%  of
ncident  cases  (Banerjee  et  al.,  2009).  Prevalence  rates  for
pilepsy  in  Spain  are  between  5  and  10/1000,  giving  a  total
f  approximately  400,000  individuals  with  the  condition,
f  which  57%  have  focal  epilepsy  (Sempere  et  al.,  2002).
espite  the  availability  of  effective  treatments  for  epilepsy
Glauser  et  al.,  2006;  Johannessen  and  Ben-Menachem,
006),  it  has  been  estimated  that  anywhere  between  15%
nd  40%  of  patients  fail  to  achieve  adequate  seizure  control
Brodie  and  Kwan,  2002;  Kwan  and  Brodie,  2004;  Picot
t  al.,  2008;  Rufo-Campos  et  al.,  2008).  Patients  with  focal
pilepsy  in  particular  are  more  likely  to  have  drug-resistant
pilepsy  (DRE)  (Picot  et  al.,  2008).  The  lack  of  satisfactory
eizure  control  in  these  patients  can  have  a  substantial
egative  impact  on  patient  health  related  quality  of  life
HRQOL),  with  studies  showing  poorer  HRQOL  in  those  with
requent  seizures  (at  least  one  a  month)  than  in  those  with
nfrequent  or  no  seizures  (Baker  et  al.,  1997;  Villanueva
t  al.,  2013).  Seizure  severity  has  also  been  shown  to  be  a
ood  predictor  of  poorer  HRQOL  (Taylor  et  al.,  2011).
From  a  patient  perspective,  the  combination  of  poor
eizure  control  and  higher  rates  of  depressive  symptoms  can
ave  a  highly  deleterious  effect  on  HRQOL  (Jacoby  et  al.,
009;  Park  et  al.,  2010;  Taylor  et  al.,  2011),  and  scores  on
epression  scales  have  been  shown  to  be  the  strongest  and
ost  consistent  predictors  of  HRQOL  in  epilepsy  patients
Tracy  et  al.,  2007;  Luoni  et  al.,  2011).  To  date,  however,
here  have  been  relatively  few  studies  into  the  prevalence
f  depression  in  DRE  or  its  impact  on  HRQOL,  although
 recently  published  study  found  a  rate  of  major  depres-
ion  in  DRE  patients  of  23%  compared  to  8.3%  in  non-DRE
atients  (Villanueva  et  al.,  2013).  The  primary  objective
f  the  present  study  was  to  determine  the  prevalence  of
epressive  symptoms  in  patients  with  DRE  compared  to
hose  with  controlled  focal  epilepsy  (CFE)  and  evaluate  the
mpact  of  depressive  symptoms  on  HRQOL  in  the  two  groups.
econdary  study  objectives  were  to  analyze  the  correlation
etween  the  Montgomery  Asberg  (MADRS)  and  Beck  Depres-
ion  Inventory  (BDI),  to  investigate  socio-demographic  and
linical  factors  related  to  the  severity  of  depressive  symp-
oms  in  these  patients,  to  describe  HRQOL  in  the  two  groups,
nd  to  explore  the  socio-demographic  and  clinical  factors
ssociated  with  poor  HRQOL.
ethodstudy  design
his  was  an  observational,  cross-sectional,  multicenter
ohort  study  carried  out  in  Spanish  neurology  outpatient
s
i
s
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studies,  the  rate  of  depressive  symptoms  was  high  (60%  in  DRE
 and  BDI-II  showed  a  positive  correlation.  Prior  to  the  study,
diagnosed  in  a  large  proportion  of  patients.  Clinical  diagnosis
seizure  frequency  was  associated  with  poorer  mean  QOLIE-31
linics.  Patients  were  recruited  consecutively  by  a  total  of
30  neurologists  in  99  centers  throughout  Spain  and  assigned
o  one  of  two  study  groups  (DRE  or  CFE).  In  accordance
ith  International  League  Against  Epilepsy  (ILAE)  guide-
ines,  patients  with  DRE  were  deﬁned  as  those  in  which
ustained  seizure  freedom  was  not  achieved  after  ade-
uate  trials  of  two  tolerated,  appropriately  chosen  and
sed  antiepileptic  drug  schedules  (whether  monotherapies
r  in  combination)  (Kwan  et  al.,  2010).  Patients  with  CFE
ere  those  whose  seizures  had  been  controlled  at  least  dur-
ng  the  previous  12  months.  Patients  were  included  in  the
tudy  between  November  2011  and  August  2012  and  data
as  collected  either  from  medical  records  or  by  question-
aires  completed  by  the  patient  at  the  time  of  the  study
isit.
The  study  was  carried  out  in  accordance  with  The  Code
f  Ethics  of  the  World  Medical  Association  (Declaration  of
elsinki)  for  experiments  involving  humans,  and  ethical
pproval  was  obtained  from  the  Ethics  Committee  of  one
f  the  participating  hospitals.
tudy  population
o  be  included  in  the  study  patients  had  to  be  aged  18
ears  or  over,  have  a  conﬁrmed  clinical  diagnosis  of  focal
pilepsy,  and  have  provided  signed  informed  consent  to
articipate.  Patients  were  excluded  if  they  had  a  chronic
isease  that  could  interfere  with  the  study  results,  such  as
eart  disease,  diabetes,  respiratory  failure,  chronic  pain,
heumatologic  diseases  or  digestive  diseases,  or  if,  in  the
pinion  of  the  clinical  investigator,  they  had  difﬁculties  in
nderstanding,  reading,  and  writing  or  a  degree  of  cognitive
mpairment  which  would  prevent  them  from  completing
he  study  questionnaires.
ample  size
he  study  sample  size  was  designed  to  determine  the  preva-
ence  of  depressive  symptoms  in  patients  with  drug-resistant
ocal  epilepsy,  and  to  evaluate  the  impact  of  depressive
ymptoms  on  HRQOL.  The  prevalence  of  depressive  symp-
oms  in  patients  with  focal  epilepsy  was  estimated  at  43%
Kanner  et  al.,  2004),  which  meant  that  for  a  precision
f  4.5  points  and  a  signiﬁcance  level  of  0.05,  a  minimum
ample  size  of  465  patients  would  be  required.  Assum-
ng  10%  of  invalid  questionnaires,  the  necessary  sample
ize  was  500  patients,  or  250  each  in  the  CFE  and  DRE
roups.
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Study  endpoints  and  variables
The  study’s  primary  endpoint  was  the  prevalence  of  depres-
sive  symptoms.  At  the  time  this  study  was  initiated  the
Montgomery—Asberg  Depression  Rating  Scale  (MADRS)  (Lobo
et  al.,  2002)  and  the  Beck  Depression  Inventory  (BDI-II)  (Beck
et  al.,  1996;  Sanz  et  al.,  2003)  had  been  frequently  used
in  the  epilepsy  population.  In  addition,  most  epilepsy  spe-
cialists  in  Spain  are  familiar  with  these  scales,  using  them
regularly  in  clinical  practice  and  drug  trials.  Because  of  this
we  chose  MADRS  and  BDI-II  instead  of  other  depression  scales
for  this  study.  The  MADRS  is  an  interview-administered  ques-
tionnaire  consisting  of  10  items  which  measure  10  different
depressive  symptoms  over  the  past  week.  Each  symptom
is  evaluated  on  a  7  point  Likert  scale  and  the  total  score
ranges  from  0  points  (no  depression)  to  60  (maximum  level
of  depression).  A  score  below  10  points  is  considered  to  indi-
cate  absence  of  depressive  disorder,  so  for  the  purposes
of  this  study  depressive  symptoms  was  considered  to  be
present  in  any  patient  with  a  score  of  10  or  above.
The  BDI-II  is  a  widely  used  self-administered  scale  con-
sisting  of  21  items  to  evaluate  the  severity  of  depressive
symptoms.  Each  BDI-II  item  consists  of  four  statements,
scored  0—3,  with  higher  scores  indicating  increasing  symp-
tom  severity.  Respondents  are  instructed  to  describe  the  way
they  have  been  feeling  during  the  past  two  weeks.  The  ﬁnal
score  can  range  between  0  and  63  and  a  score  of  10  points
or  over  was  considered  to  indicate  presence  of  depressive
symptoms.
In  order  to  assess  the  effect  of  depressive  symptoms
on  HRQOL,  patients  also  completed  the  Quality  of  Life
in  Epilepsy  Inventory  (QOLIE-31)  (Cramer  et  al.,  1998;
Torres  et  al.,  1999).  This  self-administered  instrument  meas-
ures  disease-speciﬁc  HRQOL  in  patients  with  epilepsy  and
consists  of  31  items  covering  seven  HRQOL  dimensions
(seizure  worry,  overall  quality  of  life,  emotional  well-being,
energy/fatigue,  cognitive  disorders,  medication  effects,
and  social  functioning).  The  overall  score  ranges  from
0  (worst  possible  HRQOL)  to  100  (best  possible  HRQOL).
Although  pre-deﬁned  cut-points  are  not  available  with  the
questionnaire,  studies  in  epilepsy  patients  have  suggested
the  following  possible  categorization:  excellent  (91—100),
very  good  (81—90),  good  (71—80),  fair  (61—70),  and  poor
(≤60)  (Pérez  Galdós,  2010).
Socio-demographic  variables  collected  in  the  study
included  age  (in  years),  gender,  ethnicity  (Caucasian,
Hispanic,  African,  Asian,  other),  educational  level,  employ-
ment  status,  residence,  and  impact  of  disease  on
place  of  residence.  Clinical  variables  included  general
clinical  characteristics  such  as  current  weight,  height,
body  mass  index  (BMI),  and  presence  of  concomitant
chronic  diseases  (cardiovascular,  gastrointestinal/hepatic,
endocrine/metabolic,  genito-urinary,  infectious,  musculo-
skeletal,  neurological/psychiatric,  respiratory,  neoplastic,
other).  Epilepsy  and  depressive  symptoms  related  variables
included  time  since  diagnosis  of  epilepsy,  epilepsy  type,
drug  treatment  for  epilepsy,  clinical  diagnosis  of  depres-
sive  symptoms  (yes/no),  date  of  diagnosis  of  depressive
symptoms  or  date  of  onset  of  depressive  symptoms,  drug
treatment  for  depressive  symptoms,  and  family  history  of
depressive  symptoms.  Information  on  alcohol  and  drug  con-
sumption  was  also  collected.
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tatistical  analysis
o  describe  the  sample  and  to  compare  groups  on  study  end-
oints,  continuous  variables  were  described  using  means
nd  standard  deviations,  or  medians  and  interquartile
anges  as  appropriate.  Categorical  variables  were  described
sing  absolute  values  and  percentages.  Student’s  t  test
nd  analysis  of  variance  (ANOVA)  or  their  non-parametric
quivalent,  were  used  for  between  group  comparisons  of
ontinuous  variables,  and  a  chi-square  test  for  linear  trend
Mantel—Haenszel)  or  Fisher’s  exact  test  were  used  to
nalyze  categorical  variables.  In  post-hoc  comparisons,  a
onferroni  adjustment  was  used  to  correct  for  multiple
omparisons.  In  all  statistical  tests  with  outcome  variables
tatistical  signiﬁcance  was  set  at  p  <  0.01.
The  prevalence  of  depressive  symptoms  was  analyzed
ased  on  responses  to  the  MADRS  and  BDI-II.  Cases  were
eﬁned  as  those  scoring  10  or  more  on  MADRS  or  the
DI-II.  Prevalence  was  calculated  as  the  number  of  cases
ivided  by  the  total  population  included  for  analysis.  As
reatment  for  depressive  symptoms  could  lead  to  lower
cores  on  the  MADRS  and  BDI-II,  we  also  calculated  preva-
ence  rates  for  depressive  symptoms  in  which  we  included
s  cases  any  patient  who  was  also  taking  medication  for
epressive  symptoms,  whatever  their  score  on  the  screening
uestionnaires.
To  analyze  the  relationship  between  socio-demographic
nd  clinical  characteristics  and  scores  on  the  depression  and
RQOL  scales,  we  initially  performed  bivariate  tests  of  asso-
iation  using  ANOVA  for  categorical  variables  and  Pearson
r  Spearman  correlations  for  continuous  variables.  Socio-
emographic  and  clinical  variables  showing  a  statistically
igniﬁcant  relationship  (p  ≤  0.1)  with  depressive  symptoms
r  HRQOL  in  bivariate  analysis  were  then  included  in  a  linear
egression  model  to  determine  whether  they  independently
ontributed  to  depressive  symptoms  and  HRQOL  scores.  Vari-
bles  that  improved  model  ﬁt  and  which  were  signiﬁcant  at
 <  0.05  in  the  multivariate  model  were  selected  using  the
ackward  method.  Model  ﬁt  was  assessed  using  r-squared.
ll  analyses  were  performed  using  the  statistical  package
AS  v.  9.2  for  Windows.
esults
 total  of  515  patients  with  focal  epilepsy  were  included.  Of
hose,  267  (51.8%)  had  CFE  and  248  (48.2%)  had  DRE.
Table  1  shows  the  socio-demographic  characteristics  of
he  sample  as  a  whole  and  by  sub-group.  In  the  overall  sam-
le,  mean  (SD)  patient  age  was  44.3  (15.4)  years  and  50.5%
ere  male,  primarily  Caucasian,  with  primary  level  educa-
ion  (32.7%),  and  currently  employed  (39.2%).  91.7%  of  the
ample  were  living  with  family  members  and  20.1%  reported
hat  the  disease  affected  their  living  arrangements.  There
ere  statistically  signiﬁcant  differences  between  the  two
tudy  groups  in  terms  of  employment  situation  (39.2%
mployed  in  the  CFE  group  compared  to  29.0%  in  the  DRE
roup;  p  <  0.001)  and  whether  illness  affected  the  place  of
esidence  (20.1%  in  CFE  vs  29.7%  in  DRE;  p  <  0.001).
Table  2  shows  the  sample’s  clinical  characteristics.  In
pproximately  three-quarters  of  the  patients,  focal  epilepsy
as  the  initial  diagnosis  and  almost  all  were  receiving
160  M.E.  Garcia  et  al.
Table  1  Socio-demographic  characteristics  of  the  overall  sample  and  by  study  group.
Controlled  focal
epilepsy  (N  =  267)
Drug  resistant  focal
epilepsy  (N  =  248)
Overall  (N  =  515)  p  Value
Age  (years),  mean  (SD)  44.2  (16.1)  44.5  (14.6)  44.3  (15.4)  0.814
Sex, male,  N  (%)  138  (51.7%)  122  (49.2%)  260  (50.5%)  0.572
Ethnicity, N  (%)
Caucasian  257  (96.6%)  240  (96.8%)  497  (96.7%) 0.920
Hispano-American  9  (3.4%)  8  (3.2%)  17  (3.3%)
Education,  N  (%)
No formal  education  9  (3.4%)  13  (5.2%)  22  (4.5%) 0.473
Primary education  84  (31.6%)  84  (33.9%)  168  (32.7%)
Secondary  level  62  (23.3%)  58  (23.4%)  120  (23.3%)
Professional  training  45  (16.9%)  47  (19.0%)  92  (17.9%)
University  or  equivalent  66  (24.8%)  46  (18.5%)  112  (21.8%)
Employment  situation,  N  (%)
Student  16  (6.0%)  15  (6.0%)  31  (6.0%) <0.001
Temporary  sick  leave  7  (2.6%)  14  (5.6%)  21  (4.1%)
Permanent  disability  6  (2.2%)  23  (9.3%)  29  (5.6%)
Currently  employed  130  (48.7%)  72  (29.0%)  202  (39.2%)
Unemployed  31  (11.6%)  41  (16.5%)  72  (14.0%)
Retired 52  (19.5%)  58  (23.4%)  110  (21.4%)
Looking after  home  25  (9.4%)  25  (10.1%)  50  (9.7%)
Place of  residence,  N  (%)
Living  alone  20  (7.5%)  19  (7.7%)  39  (7.6%) 1.000*
Living  with  family 245  (91.8%)  227  (91.5%)  472  (91.7%)
Retirement  home 2  (0.7%) 2  (0.8%)  4  (0.8%)
Illness affects  place  of  residence,  yes,  N  (%) 30  (11.3%) 73  (29.7%) 103  (20.1%)  <0.001
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ntiepileptic  treatment  at  the  time  of  the  study  visit,  with
 mean  of  2  antiepileptic  drugs  (AED).  The  number  of  AEDs
as  signiﬁcantly  higher  in  the  DRE  group.  The  proportion  of
atients  with  co-morbidities  was  very  similar  between  the
wo  study  groups  (37.5%  in  CFE  and  33.3%  in  DRE)  and  15.9%
f  patients  had  a  previous  diagnosis  of  clinical  depressive
ymptoms;  the  proportion  of  patients  with  a  prior  diagno-
is  of  clinical  depressive  symptoms  was  substantially  higher
n  the  DRE  group  than  in  the  CFE  group  (22.6%  vs  9.7%,
espectively;  p  <  0.001).
Fig.  1  and  Table  3  show  the  prevalence  of  depressive
ymptoms  in  the  two  study  groups  according  to  the  MADRS
nd  BDI-II,  using  raw  scores  and  scores  adjusted  to  take  into
ccount  patients  taking  medication  for  depressive  symp-
oms.  Both  questionnaires  showed  much  higher  rates  of
epressive  symptoms  in  the  DRE  group.  Using  the  MADRS
cale,  prevalence  of  depressive  symptoms  in  the  DRE  group
as  almost  double  that  of  the  CFE  group  (59.3%  vs  30.3%,
espectively,  using  unadjusted  data  and  62.1%  vs  32.6%  using
djusted  data;  p  <  0.001).  Similar  results  were  seen  with  the
DI,  with  an  overall  depressive  symptoms  rate  of  48.1%  using
he  ≥10  point  threshold,  and  considerably  higher  rates  of
epressive  symptoms  in  the  DRE  group  compared  to  CFE
atients  (61.9%  vs  35.3%,  respectively,  using  unadjusted
ata,  and  64.8%  vs  37.2%  using  adjusted  data;  p  <  0.001).
b
o
to missing responses.
With  regard  to  the  degree  of  association  and  correlation
etween  the  two  scales  (see  Fig.  2),  we  found  an  overall
revalence  rate  for  depressive  symptoms  of  37.2%  when  we
nly  included  patients  who  were  conﬁrmed  as  cases  on  both
cales.  The  Pearson  correlation  coefﬁcient  between  the  two
cales  was  high,  at  r  =  0.80.  Multivariate  modeling  showed
hat  variables  associated  with  higher  MADRS  and  BDI-II  scores
more  severe  depressive  symptoms)  included  being  in  the
RE  group,  having  a  lower  level  of  education,  being  unem-
loyed  or  on  temporary  sick  leave,  receiving  treatment  for
epressive  symptoms,  and  having  certain  types  of  co-morbid
llnesses.  In  both  cases,  the  strongest  contributor  to  higher
ADRS  and  BDI-II  scores  was  having  a  diagnosis  of  depres-
ive  symptoms  but  being  untreated  for  the  condition.  Both
odels  showed  acceptable  goodness  of  ﬁt.
Regarding  the  HRQOL  of  patients  with  DRE  and  CFE,
hose  with  adequately  controlled  seizures  experienced  con-
iderably  better  HRQOL  than  those  with  poorer  control  (see
ig.  3).  This  was  true  on  all  dimensions  of  the  QOLIE-31  and
n  the  overall  score  (mean  [SD]  of  69.9  [16.5]  for  the  CFE
roup  and  54.2  [18.9]  in  the  DRE  group).  All  differences
etween  the  two  groups  on  QOLIE-31  dimensions  and  on
verall  score  were  statistically  signiﬁcant  (p  <  0.001).
As  shown  in  Fig.  4,  the  presence  of  depressive  symp-
oms  led  to  poorer  QOLIE-31  scores  in  both  study  groups.
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Table  2  Clinical  characteristics  of  the  overall  sample  and  by  study  group.
Controlled  focal
epilepsy  (n  =  267)
Drug  resistant  focal
epilepsy  (n  =  248)
Overall  (n  =  515)  p  Value
Focal  seizure  at  diagnosis,  n  (%)  201  (79.4%)  175  (78.1%)  376  (78.8%)  0.724
Receiving antiepileptic  treatment,  n
(%)
264  (98.9%)  248  (100%)  512  (99.4%)  0.094
Number of  antiepileptic  drugs,  mean
(SD)
1.46  (0.61)  2.48  (0.76)  1.95  (0.85)  <0.001
Overweight/obese,  n  (%) 134  (50.2%) 123  (49.6%) 257  (49.9%) 0.860
Presence of  comorbidities,  n  (%)  99  (37.5%)  82  (33.3%)  181  (35.5%)  0.326
Most frequent  comorbidities,  n  (%)
Cardiovascular  34  (12.9%)  21  (8.5%)  55  (10.8%)  0.114
Endocrine/metabolic  30  (11.4%)  21  (8.5%)  51  (10.0%)  0.288
Neurologic/psychiatric  (not
depression  or  epilepsy)
14  (5.3%)  15  (6.1%)  29  (5.7%)  0.699
Previous clinical  diagnosis  of
depressive  symptoms,  n  (%)
26  (9.7%)  56  (22.6%)  82  (15.9%)  <0.001
Taking pharmacological  treatment  for
depressive  symptoms,  n  (%  of  those
with  diagnosis  of  depressive
symptoms)
22  (84.6%)  47  (83.9%)  69  (84.1%)  0.937
Type of  treatment,  n  (%)
Antidepressant  20  (90.9%) 44  (93.6%) 64  (92.8%) 0.686
Anxiolytic 8  (36.4%) 24  (51.1%) 32  (46.4%) 0.254
Antipsychotic  2  (9.1%)  2  (4.3%)  4  (5.8%)  0.423
Hypnotic 4  (18.2%)  6  (12.8%)  10  (14.5%)  0.552
mFamily history  of  depression  70  (27.2%)  
Depressed  patients  in  the  DRE  group  had  statistically  sig-
niﬁcant  poorer  QOLIE-31  scores  than  depressed  patients
in  the  CFE  group  on  all  dimensions,  except  seizure  worry
and  medication  effects.  Multivariate  modeling  showed  that
factors  with  a  statistically  signiﬁcant  impact  on  HRQOL  as
u
u
o
p
Fig.  1  Prevalence  of  depressive  symptoms  by  st65  (27.1%)  135  (27.2%)  0.969
easured  by  the  QOLIE-31  were  epilepsy  type,  living  sit-
ation,  and  the  severity  of  depressive  symptoms  measured
sing  the  MADRS  and  BDI-II.  Caucasian  patients  scored  higher
n  QOLIE-31  scores  (better  HRQOL)  than  Hispano-American
atients.  Patients  with  DRE  had  signiﬁcantly  poorer  HRQOL
udy  group  based  on  MADRS  and  BDI-II  scores.
162  M.E.  Garcia  et  al.
Table  3  Prevalence  (95%  conﬁdence  interval)  of  depressive  symptoms  by  study  group  based  on  MADRS  and  BDI-II  mean  scores.
Controlled  focal  epilepsy  Drug  resistant  focal  epilepsy  Overall
MADRS  scores1 30.3  (24.8—35.8)  59.3  (53.2—65.4)  44.3  (40.0—48.6)
Adjusted MADRS  scores2 32.6  (27.0—38.2)  62.1  (56.0—68.2)  46.8  (42.5—51.1)
BDI-II scores1 35.3  (29.6—41.0)  61.9  (55.8—68.0)  48.1  (43.8—52.5)
Adjusted BDI-II  scores2 37.2  (31.4—43.0)  64.8  (58.8—70.8)  50.5  (46.2—54.8)
1 Raw scores.
2 Adjusted scores taking into account patients on antidepressant treatment.
ation
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FFig.  2  Scatter  plot  showing  associ
han  those  with  CFE  as  did  those  with  higher  levels  of  depres-
ive  symptoms.  Even  minimal  signs  of  depressive  symptoms
n  either  of  the  depression  scales  led  to  a  substantial
eduction  in  QOLIE-31  scores.  The  multivariate  model  used
t
F
b
ig.  3  Mean  overall  and  dimension  scores  on  the  QOLIE-31  questio between  BDI-II  and  MADRS  scores.
howed  a  high  goodness  of  ﬁt,  and  explained  68.7%  of
he  variance  in  the  dependent  variable  (QOLIE-31  score).
urther  analysis  showed  that  the  QOLIE-31  score  decreased
y  almost  one  point  for  each  one  point  increase  on  the  BDI-II,
nnaire  by  study  group  (bars  show  95%  conﬁdence  intervals).
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oFig.  4  Scores  on  QOLIE-31  dimensions  by  study  group  an
compared  to  a  decrease  of  one  point  on  QOLIE-31  for  each
two  point  increase  on  the  MADRS,  suggesting  that  differ-
ences  in  score  on  the  BDI-II  had  a  greater  impact  on  QOLIE-31
scores  (data  not  shown).
Discussion
In  this  study,  we  provide  further  evidence  of  the  preva-
lence  of  depression  and  depressive  symptoms  in  patients
with  DRE  compared  to  patients  with  CFE  in  a  Spanish
cohort.  After  including  patients  who  were  receiving  some
form  of  anti-depressant  medication,  we  found  a  signiﬁcant
rate  of  depressive  symptoms  which  was  much  higher  in  the
DRE  group  than  in  patients  with  CFE.  We  also  found  that
QOLIE  31  dimensions  and  overall  scores  were  considerably
worse  in  DRE  patients  than  in  CFE  patients.  Furthermore,
we  observed  that  patients  with  depressive  symptoms  have
worse  HRQOL  even  when  seizures  are  controlled.  This  indi-
cates  a  strong  correlation  between  depressive  symptoms,
HRQOL  and  seizure  control.  The  lowest  HRQOL  was  found
in  patients  with  DRE  and  depressive  symptoms.  Risk  factors
for  the  presence  of  depressive  symptoms  included  having  a
lower  level  of  education,  being  on  sick  leave  or  unemployed,
and  having  certain  co-morbidities  (diseases  of  the  blood  and
blood  forming  organs,  and  cerebrovascular  disease).  While
the  study  design  did  not  allow  us  to  determine  whether  these
were  causal  factors  for  depressive  symptoms,  the  results  do
provide  an  indication  of  characteristics  to  take  into  account
when  deciding  on  the  likelihood  of  depressive  symptoms
in  individual  patients.  Further  research  is  needed,  on  the
other  hand,  to  conﬁrm  the  extent  to  which  co-morbidities
such  as  hematological  or  cerebrovascular  diseases  are  in  fact
independent  risk  factors  for  depressive  symptoms,  as  the
numbers  in  the  present  sample  in  both  cases  were  small,
and  extreme  results  in  such  small  numbers  could  have  unduly
biased  the  results.
This  is  one  of  very  few  epidemiological  studies  of  this
type  performed  in  a  Spanish  population.  We  consider  our
ﬁndings  to  be  clinically  relevant  because  they  highlight
aspects  related  to  the  clinical  practice  and  management  of
patients  with  FE  which  may  require  further  attention.  The
results  of  the  current  study  underline  the  widespread  nature
i
u
t
acording  to  presence  or  absence  of  depressive  symptoms.
f  depressive  symptoms  in  FE  patients,  particularly  those
ith  DRE,  and  provide  further  evidence  of  the  association
etween  depressive  symptoms,  HRQOL  and  seizure  con-
rol  and  thus  in  the  evolution  of  the  disease.  Furthermore,
hey  suggest  that  depressive  symptoms  may  be  considerably
ndertreated  in  this  population,  a  very  important  ﬁnding
onsidering  how  it  can  modify  the  prognosis  of  epilepsy.
lthough  we  found  prevalence  rates  of  almost  50%  for
epressive  symptoms,  only  15.9%  of  the  overall  sample  had  a
revious  clinical  diagnosis  of  depressive  symptoms,  indicat-
ng  that  a  high  percentage  of  patients  were  underdiagnosed
nd  undertreated.  This  has  been  observed  in  other  stud-
es;  for  example  Friedman  et  al.  (2009),  using  systematic
creening,  found  at  least  65%  of  patients  with  previously
ndiagnosed  depression,  while  Boylan  et  al.  (2004)  reported
n  underdiagnosis  rate  of  37%,  with  only  17%  of  patients
eceiving  anti-depressants.
The  study  results  conﬁrm  previous  ﬁndings  of  a  tendency
oward  higher  rates  of  depressive  symptoms  in  epilepsy
atients,  particularly  in  DRE  patients,  though  some  ear-
ier  studies  found  lower  overall  rates  than  those  reported
ere.  Picot  et  al.  (2008)  found  rates  of  psychiatric  disor-
ers,  mainly  anxiety  or  depression,  of  37%  in  patients  with
RE  and  18.9%  in  patients  with  controlled  epilepsy,  while
illanueva  et  al.  (2013)  reported  rates  of  23%  versus  8.3%,
espectively,  for  the  same  groups  (Villanueva  et  al.,  2013).
anner  et  al.  (2004),  on  the  other  hand,  reported  depression
ates  of  43%  in  DRE  patients  and  lifetime  prevalence  rates
f  30%  to  35%  in  general  samples  of  people  with  epilepsy
Kanner  et  al.,  2012),  rates  which  are  closer  to  those  found
n  our  study.  Other  authors  have  noted  the  variability  in
revalence  rates  for  depression  reported  in  different  stud-
es,  with  a  range  from  8%  to  48%  (Hermann  et  al.,  2000).
o  some  extent,  rates  will  depend  on  methodology.  For
xample,  Picot  et  al.  (2008)  based  their  ﬁndings  on  physi-
ian  reports  of  psychiatric  disorders,  while  Villanueva  et  al.
2013)  used  the  Neurological  Disorders  Depression  Inventory
or  Epilepsy  (NDDI-E)  (Gilliam  et  al.,  2006)  to  identify  cases
f  depression.  The  cut-points  for  depression  used  with  an
nstrument  can  also  impact  depression  rates.  In  our  study,
sing  the  standard  recommended  cut-point  of  10  points  on
he  BDI-II  (Sanz  et  al.,  2003)  led  to  a  prevalence  rate  of  50.5%
fter  including  patients  receiving  medication  for  depressive
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ymptoms;  this  compared  to  a  rate  of  40%  using  the  cut-
oint  of  12  points  recommended  by  Jones  and  colleagues
Jones  et  al.,  2005).  It  should  also  be  remembered  that,
hile  respondents  scoring  under  the  cut-point  on  the  BDI-II
re  very  unlikely  to  have  major  depression  (excellent  nega-
ive  predictive  value),  approximately  50%  of  those  scoring
bove  the  cut-point  are  likely  to  have  major  depression
Jones  et  al.,  2005).  As  the  importance  of  detecting  depres-
ive  symptoms  in  patients  with  epilepsy  has  been  clearly
emonstrated  in  several  studies,  we  believe  it  is  essential  to
ork  toward  a  more  standardized  methodology  for  its  detec-
ion.  Part  of  that  would  involve  determining  the  best  scale  to
valuate  depressive  symptoms  in  this  group  of  patients.  That
ould  help  minimize  the  variability  in  results  and  improve
omparability  between  studies.
Furthermore,  given  the  relevant  prevalence  of  depres-
ive  symptoms  in  this  population,  we  should  reinforce  the
mportance  of  its  identiﬁcation  and  the  need  to  promptly
nitiate  management  strategies,  such  as  identifying  AEDs
hat  could  be  causing  or  worsening  depressive  symptoms,
rescribing  antidepressants  or  referring  patients  to  psychia-
rists  or  psychotherapy,  that  in  some  cases  show  better  long
erm  beneﬁts  over  medication.
A  strong  point  of  the  present  study  was  the  use  of
wo  different  scales  to  assess  the  presence  of  depressive
ymptoms.  The  results  were  similar  in  terms  of  the  rates
f  depressive  symptoms  identiﬁed,  suggesting  that  the
ndings  were  robust.  Both  measures  also  showed  similar
esults  when  included  in  multivariate  modeling  to  test  the
mpact  of  depressive  symptoms  on  HRQOL.  As  in  previous
tudies,  we  found  that  the  presence  of  depressive  symp-
oms  was  the  strongest  predictor  of  poor  HRQOL  in  these
atients  (Tracy  et  al.,  2007;  Luoni  et  al.,  2011).  It  is  also
nteresting  to  note  that  the  presence  of  minimal  depressive
ymptoms  on  the  MADRS  or  the  BDI-II  had  a  signiﬁcant
egative  effect  on  QOLIE-31  scores.  This  suggests  that  even
oderate  improvements  in  depressive  symptoms  might
ead  to  considerable  gains  in  HRQOL.  Another  strong  point
f  the  study  was  the  relatively  large  sample  size  and  the
act  that  patients  were  included  from  a  large  number  of
enters  throughout  Spain.  Both  of  these  aspects  support
he  generalizability  of  the  results.
Limitations  of  the  study  include  the  fact  that,  due  to  the
tudy  design,  it  was  not  possible  to  determine  the  direction
f  any  effect  of  the  variables  in  the  multivariate  models  on
he  dependent  variables.  Thus,  it  is  not  possible  to  deter-
ine,  for  example,  whether  DRE  is  a  contributing  factor  to
epressive  symptoms,  or  vice  versa.  Some  current  think-
ng  suggests  a  bi-directional  relationship  (Kanner,  2011),
hereby  the  presence  of  depressive  symptoms  might  be  one
f  a  series  of  risk  factors  for  poor  response  to  therapy  with
EDs  (Petrovski  et  al.,  2010).  Another  limitation  of  the  study
s  that  we  did  not  collect  information  on  seizure  frequency
rior  to  inclusion.  It  was  therefore  not  possible  to  deter-
ine  the  possible  effect  of  seizure  frequency  on  QOLIE-31
cores  or  to  examine  its  association  with  MADRS  and  BDI-
I  scores.  Including  seizure  frequency  in  modeling  of  the
OLIE-31  score  may  have  reduced  the  impact  of  depres-
ive  symptoms  to  some  extent,  but  other  studies  have  shown
hat  depressive  symptoms  have  a  stronger  effect  on  HRQOL
han  seizure  frequency  (Tracy  et  al.,  2007;  Luoni  et  al.,
011).
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Finally,  generalizability  of  results  may  be  somehow
imited  because  the  sample  of  participating  sites  and  the
umber  of  patients  per  center  were  no  chosen  following
 population  and  geography-based  sampling  methodology;
owever,  the  large  number  of  investigators  and  healthcare
ocations  with  geographical  spread  across  Spain,  and  con-
ecutive  recruitment  of  patients  make  it  unlikely  that  any
erious  bias  may  reduce  signiﬁcantly  results  and  conclusions
obustness.
In  conclusion,  this  study  provides  further  evidence  of  the
ervasive  nature  of  depressive  symptoms  among  people  with
pilepsy  and,  particularly,  in  those  with  DRE.  Prompt  iden-
iﬁcation  and  treatment  of  affected  individuals  is  advised.
uality  of  life  is  most  strongly  affected  in  those  with  DRE  and
elf-reported  depressive  symptoms.  Despite  the  growing  evi-
ence  of  the  correlation  between  depressive  symptoms  and
pilepsy,  it  appears  to  be  still  underdiagnosed  and  under-
reated.  The  co-morbid  nature  of  depressive  symptoms  and
pilepsy  suggests  the  need  for  a  coordinated  approach  to
reatment  and  future  randomized  studies  should  determine
he  extent  to  which  appropriate  management  of  depressive
ymptoms  in  patients  with  DRE  affects  HRQOL  and  seizure
ontrol.
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